Call for Papers  

Article Details

General Review Article

Targeting Microenvironment of Melanoma and Head and Neck Cancers in Photodynamic Therapy

[ Vol. 29 , Issue. 18 ]


Ivana Ratkaj, Martina Mušković and Nela Malatesti*   Pages 3261 - 3299 ( 39 )


Background: Photodynamic therapy (PDT), in comparison to other skin cancers, is still far less effective for melanoma, due to the strong absorbance and the role of melanin in cytoprotection. The tumour microenvironment (TME) has a significant role in tumour progression, and the hypoxic TME is one of the main reasons for melanoma progression to metastasis and its resistance to PDT. Hypoxia is also a feature of solid tumours in the head and neck region that indicates negative prognosis.

Objective: The aim of this study was to individuate and describe systematically the main strategies in targeting the TME, especially hypoxia, in PDT against melanoma and head and neck cancers (HNC), and assess the current success in their application.

Methods: PubMed was used for searching, in MEDLINE and other databases, for the most recent publications on PDT against melanoma and HNC in combination with the TME targeting and hypoxia.

Results: In PDT for melanoma and HNC, it is very important to control hypoxia levels, and amongst the different approaches, oxygen self-supply systems are often applied. Vascular targeting is promising, but to improve it, optimal drug-light interval, and formulation to increase the accumulation of the photosensitiser in the tumour vasculature, have to be established. On the other side, the use of angiogenesis inhibitors, such as those interfering with VEGF signalling, is somewhat less successful than expected and needs to be further investigated.

Conclusion: The combination of PDT with immunotherapy by using multifunctional nanoparticles continues to develop and seems to be the most promising for achieving a complete and lasting antitumour effect.


Photodynamic therapy, photosensitisers, tumour microenvironment, hypoxia, melanoma, head and neck cancer.


Department of Biotechnology, University of Rijeka, Department of Biotechnology, University of Rijeka, Department of Biotechnology, University of Rijeka

Read Full-Text article